Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of GABAA Receptor Modulation by AP-325 on Insulin

NCT05160272 is registered in ClinicalTrials.gov with The Deutsche Diabetes Forschungsgesellschaft e.V. as lead sponsor.

NCT NCT05160272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05160272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of GABAA Receptor Modulation by AP-325 on Insulin
Lead sponsor
The Deutsche Diabetes Forschungsgesellschaft e.V.
Phase
Phase 2
Overall status
Completed
Start date
January 7, 2022
Completion date
December 17, 2024
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type2 diabetes